pipette
ESEspañol

Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial

Xiaoliang Zhao, Bin Zhang, Chenguang Li, Lianmin Zhang, Meng Wang, Ziqiang Tian, Shengguang Wang, Qiang Zhang, Huilai Lv, Chong Pang, Shiwang Wen, Xiaofei Wang, Wei Wei, Yu Zhang, Huang Wuhao, Jianquan Zhu, Yue Li, Chen Chen, Yao Tang, Bin Jia, Hua Zhang, Hui Chen, Sha Wang, Jun-Ye Zhang, Wenting Li, Zhongmin Maxwell Wang, Boning Li, Michelle Xia, Zhenfa Zhang, Dongsheng Yue, Changli Wang

Peer-reviewed journalReal-world use

In the authors' words

In a nonrandomized phase 2 trial, patients with resectable non-small cell lung cancer received perioperative ivonescimab as monotherapy or with chemotherapy, leading to encouraging pathological response rates in both cohorts, and sustained circulating tumor DNA negativity throughout neoadjuvant therapy may be predictive of response.

Main resultThe abstract does not state a limitation.

Appeared: Friday, November 6. Nature Medicine. Peer-reviewed journal.

DOI: 10.1038/s41591-026-04745-4